ipamorelin safety adverse effects cjc-1295 CJC-125 & Ipamorelin Peptide Therapy ipamorelin clinical trials safety adverse

Description

doi: 10.1080/0284186X.2017.1398836 64 KobayashiMSatoRKomuraTIchikawaHHirashimaTOtakeSet al

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Razzaque M.S

Presterud, R

Consent for publication All authors have read the journal policies and submit this manuscript in accordance with those policies

Members of the oligopeptide transporters (OPTs) might be responsible for transport of glutathione and its derivates across the plasma membrane, however the opt1-3 and opt6 mutants tested in our study did not exhibit any phenotype difference to WT when exposed to AITC